Eikon Therapeutics Archives - Medical Design Sourcing

[Adobe Stock]

As the year draws to a close, it is clear that molecular science and diagnostics is the hottest funding area in the biotech industry. In an analysis of 50 of the best-funded biotechs of 2023 focused on human health, molecular and science and diagnostics startups collectively attracting roughly $945 million, dwarfing the figures in other segments. The next popular two niches, gene therapies and oncology, had average funding levels of approximately $245 million and $170 million, respectively. While AI has received a significant amount of attention this year, biotechs specializing in that field garnered an average funding of only about $66 million. Outside of the life sciences, startups with a broader focus on AI raised a cumulative average of $202.47 million, based on an analysis of close to 1000 companies.

Caris Life Sciences has raised nearly $1.7B to date

In terms of best-funded companies overall,…

A company that sends medical teams on house calls had one of the largest venture capital deals of 2022. [Photo courtesy of Dispatch Health]

The $3 billion launch of a biotech focused on cellular rejuvenation was 2022’s largest healthcare venture capital deal in the U.S. and Europe.

That’s according to a ranking provided to Medical Design & Outsourcing by Silicon Valley Bank (SVB), which ranked the deals using its own proprietary information and data from Pitchbook.

The biopharma sector represented three of the 10 largest VC deals. Diagnostics/tools had two deals on the list, taking the No. 2 and 3 spots. The healthtech sector had four deals on the list.

Only one device developer ranked in 2022’s top 10, just like the year before, when CMR Surgical’s $600 million Series D financing round was the fifth-largest deal of 2021. (Healthtech deals dominated the prior-year list by tak…